Table 1.
Clinicopathologic characteristics of all cT1-4N0-3 breast cancer patients treated with NST between 2006 and 2016 (n = 12.461)
| Characteristics | n (%) |
|---|---|
| Year of diagnosis | |
| 2006—2009 | 2286 (18.4) |
| 2010—2013 | 4712 (37.8) |
| 2014—2016 | 5463 (43.8) |
| Age in years, median (range) | 50 (range 18–87) |
| Histologic subtype | |
| Ductal | 9832 (79) |
| Lobular | 1256 (10) |
| Adenocarcinoma NOS | 550 (4.4) |
| Mixed ductal and lobular | 307 (2.5) |
| Other | 516 (4.1) |
| Receptor status | |
| HR−/HER2− | 1751 (16.3) |
| HR−/HER2+ | 987 (9.2) |
| HR+/HER2+ | 1756 (16.4) |
| HR+/HER2− | 6243 (58.2) |
| HR and/or HER2 status | 1724 (13.8) |
| Unknown | |
| TNM status | |
| T0—1—2—3—4 | 14 (0.1)–1647 (13.2)–6595 (53)–2696 (21.6)–1509 (12.1) |
| N0—1—2—3 | 5830 (47)–5610 (45)–258 (2)–760 (8) |
| M0—X | 12,351 (99)–110 (1) |
| Lumpectomy | 5087 (41) |
| Mastectomy | 7374 (59) |
| Neoadjuvant systemic regimen | |
| Chemotherapy only | 9382 (75) |
| Chemotherapy with HER2 therapy | 2732 (22) |
| Chemotherapy with endocrine therapy | 286 (2) |
| Chemotherapy with HER2 and endocrine therapy | 61 (1) |
NOS not otherwise specified, HR hormone receptor, NST neoadjuvant systemic therapy